Q2 2026 revenue was $783M, flat sequentially, with TYVASO pressured by competition but DPI showing growth. Major clinical milestones and regulatory filings position for multi-billion-dollar opportunities in PAH and IPF, with stronger performance expected in H2 2026.Based on United Therapeutics Corp…
Q2 2026 revenues declined 2% year-over-year to $783.3 million, but net income rose 8% to $333.0 million, driven by product mix and lower tax rate. Regulatory filings and organ manufacturing initiatives signal future growth, while share repurchases boosted shareholder returns.Original document: Unit…
United Therapeutics reported second-quarter 2026 results with total revenues of $783.3 million and net income of $333.0 million. Diluted net income per share was $7.27 for the quarter, while operating income totaled $330.8 million. The company highlighted recent regulatory filings for ralinepag tab…
United Therapeutics reported results for the 2026 quarter with revenue of $783.3M, net income of $333M and diluted EPS of $7.27. Revenue declined modestly versus the prior-year quarter while profit and EPS increased.Financial Highlights¹ Reported as “Total revenues”. ² Reported as “Net income”. ³ R…
Q2 2026 revenue reached $783M, down 2% year-over-year, with strong growth in Unituxin and record Tyvaso DPI patient metrics. Late-stage clinical successes for Tyvaso in IPF and ralinepag in PAH support a robust pipeline and regulatory momentum.Original document: United Therapeutics Corporation [UTH…
Biotechnology company United Therapeutics NASDAQ:UTHRwill be reporting results this Wednesday before the bell. Here’s what you need to know.United Therapeutics missed analysts’ revenue expectations last quarter, reporting revenues of $781.5 million, down 1.6% year on year. It was a disappointing qu…
